Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer

Megumi Watanabe, Shunsuke Kagawa, Kazuya Kuwada, Yuuri Hashimoto, Kunitoshi Shigeyasu, Michihiro Ishida, Shuichi Sakamoto, Atene Ito, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Shuta Tomida, Ryuichi Yoshida, Hiroshi Tazawa, Yasuo Urata, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Gastric cancer patients positive for peritoneal cytology are at increased risk of tumor recurrence, but although a certain proportion of cytology-positive patients relapse rapidly with aggressive progression, others survive longer with conventional chemotherapies. This heterogeneity makes it difficult to stratify patients for more intensive therapy and poses a substantial challenge for the implementation of precision medicine. We developed a new approach to identify biologically malignant subpopulations in cytology-positive gastric cancer patients, using a green fluorescent protein (GFP)-expressing attenuated adenovirus in which the telomerase promoter regulates viral replication (TelomeScan, OBP-401). The fluorescence emitted from TelomeScan-positive cells was successfully quantified using a multi-mode microplate reader. We then analyzed clinical peritoneal washes obtained from 68 gastric cancer patients and found that patients positive for TelomeScan had a significantly worse prognosis. In 21 cytology-positive patients, the median survival time of those who were TelomeScan positive (235 days) was significantly shorter than that for those who were TelomeScan negative (671 days; P = 0.0062). This fluorescent virus-guided cytology detects biologically malignant cancer cells from the peritoneal washes of gastric cancer patients and may thus be useful for both therapy stratification and precision medicine approaches based on genetic profiling of disseminated cells.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Biological Products
Stomach Neoplasms
Cell Biology
Precision Medicine
Recurrence
Telomerase
Green Fluorescent Proteins
Adenoviridae
Neoplasms
Fluorescence
Viruses
Drug Therapy
Survival
Therapeutics

Keywords

  • fluorescent virus
  • gastric cancer
  • peritoneal dissemination
  • peritoneal lavage cytology
  • precision medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer. / Watanabe, Megumi; Kagawa, Shunsuke; Kuwada, Kazuya; Hashimoto, Yuuri; Shigeyasu, Kunitoshi; Ishida, Michihiro; Sakamoto, Shuichi; Ito, Atene; Kikuchi, Satoru; Kuroda, Shinji; Kishimoto, Hiroyuki; Tomida, Shuta; Yoshida, Ryuichi; Tazawa, Hiroshi; Urata, Yasuo; Fujiwara, Toshiyoshi.

In: Cancer Science, 01.01.2018.

Research output: Contribution to journalArticle

@article{a9b7163773dc480d943be1090507f4e2,
title = "Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer",
abstract = "Gastric cancer patients positive for peritoneal cytology are at increased risk of tumor recurrence, but although a certain proportion of cytology-positive patients relapse rapidly with aggressive progression, others survive longer with conventional chemotherapies. This heterogeneity makes it difficult to stratify patients for more intensive therapy and poses a substantial challenge for the implementation of precision medicine. We developed a new approach to identify biologically malignant subpopulations in cytology-positive gastric cancer patients, using a green fluorescent protein (GFP)-expressing attenuated adenovirus in which the telomerase promoter regulates viral replication (TelomeScan, OBP-401). The fluorescence emitted from TelomeScan-positive cells was successfully quantified using a multi-mode microplate reader. We then analyzed clinical peritoneal washes obtained from 68 gastric cancer patients and found that patients positive for TelomeScan had a significantly worse prognosis. In 21 cytology-positive patients, the median survival time of those who were TelomeScan positive (235 days) was significantly shorter than that for those who were TelomeScan negative (671 days; P = 0.0062). This fluorescent virus-guided cytology detects biologically malignant cancer cells from the peritoneal washes of gastric cancer patients and may thus be useful for both therapy stratification and precision medicine approaches based on genetic profiling of disseminated cells.",
keywords = "fluorescent virus, gastric cancer, peritoneal dissemination, peritoneal lavage cytology, precision medicine",
author = "Megumi Watanabe and Shunsuke Kagawa and Kazuya Kuwada and Yuuri Hashimoto and Kunitoshi Shigeyasu and Michihiro Ishida and Shuichi Sakamoto and Atene Ito and Satoru Kikuchi and Shinji Kuroda and Hiroyuki Kishimoto and Shuta Tomida and Ryuichi Yoshida and Hiroshi Tazawa and Yasuo Urata and Toshiyoshi Fujiwara",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cas.13760",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer

AU - Watanabe, Megumi

AU - Kagawa, Shunsuke

AU - Kuwada, Kazuya

AU - Hashimoto, Yuuri

AU - Shigeyasu, Kunitoshi

AU - Ishida, Michihiro

AU - Sakamoto, Shuichi

AU - Ito, Atene

AU - Kikuchi, Satoru

AU - Kuroda, Shinji

AU - Kishimoto, Hiroyuki

AU - Tomida, Shuta

AU - Yoshida, Ryuichi

AU - Tazawa, Hiroshi

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Gastric cancer patients positive for peritoneal cytology are at increased risk of tumor recurrence, but although a certain proportion of cytology-positive patients relapse rapidly with aggressive progression, others survive longer with conventional chemotherapies. This heterogeneity makes it difficult to stratify patients for more intensive therapy and poses a substantial challenge for the implementation of precision medicine. We developed a new approach to identify biologically malignant subpopulations in cytology-positive gastric cancer patients, using a green fluorescent protein (GFP)-expressing attenuated adenovirus in which the telomerase promoter regulates viral replication (TelomeScan, OBP-401). The fluorescence emitted from TelomeScan-positive cells was successfully quantified using a multi-mode microplate reader. We then analyzed clinical peritoneal washes obtained from 68 gastric cancer patients and found that patients positive for TelomeScan had a significantly worse prognosis. In 21 cytology-positive patients, the median survival time of those who were TelomeScan positive (235 days) was significantly shorter than that for those who were TelomeScan negative (671 days; P = 0.0062). This fluorescent virus-guided cytology detects biologically malignant cancer cells from the peritoneal washes of gastric cancer patients and may thus be useful for both therapy stratification and precision medicine approaches based on genetic profiling of disseminated cells.

AB - Gastric cancer patients positive for peritoneal cytology are at increased risk of tumor recurrence, but although a certain proportion of cytology-positive patients relapse rapidly with aggressive progression, others survive longer with conventional chemotherapies. This heterogeneity makes it difficult to stratify patients for more intensive therapy and poses a substantial challenge for the implementation of precision medicine. We developed a new approach to identify biologically malignant subpopulations in cytology-positive gastric cancer patients, using a green fluorescent protein (GFP)-expressing attenuated adenovirus in which the telomerase promoter regulates viral replication (TelomeScan, OBP-401). The fluorescence emitted from TelomeScan-positive cells was successfully quantified using a multi-mode microplate reader. We then analyzed clinical peritoneal washes obtained from 68 gastric cancer patients and found that patients positive for TelomeScan had a significantly worse prognosis. In 21 cytology-positive patients, the median survival time of those who were TelomeScan positive (235 days) was significantly shorter than that for those who were TelomeScan negative (671 days; P = 0.0062). This fluorescent virus-guided cytology detects biologically malignant cancer cells from the peritoneal washes of gastric cancer patients and may thus be useful for both therapy stratification and precision medicine approaches based on genetic profiling of disseminated cells.

KW - fluorescent virus

KW - gastric cancer

KW - peritoneal dissemination

KW - peritoneal lavage cytology

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85053686492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053686492&partnerID=8YFLogxK

U2 - 10.1111/cas.13760

DO - 10.1111/cas.13760

M3 - Article

C2 - 30076658

AN - SCOPUS:85053686492

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -